Press Releases

June 4, 2024

NurExone Announces Voting Results from 2024 Annual Meeting of Shareholders

May 29, 2024

NurExone Reports First Quarter 2024 Financial Results and Provides Corporate Update, moving forward with FDA guidelines for the Human Trials

May 17, 2024

NurExone Welcomes Biopharma Exec Dr. Ram Petter to Drive Strategic Collaborations

April 19, 2024

NurExone Biologic Inc. Announces Strategic Expansion to US Financial Markets with Approval of OTCQB Listing Application and DTC Eligibility

April 19, 2024

NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine

April 2, 2024

NurExone Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Company Update

March 15, 2024

NurExone’s Strategic Update: Submission of OTCQB Listing Application to Initiate US financial presence

March 8, 2024

NurExone establishing State-of-the-Art Research and Development Facility in Haifa, Israel

March 1, 2024

NurExone Presenting Novel Regulatory Pathways for Exosomes Therapies at Global Summit

February 20, 2024

NurExone’s Intellectual Property Portfolio Expands

Set layout popup